The current guidelines have recommended prolonged anticoagulation therapy with direct oral anticoagulants (DOACs) as a potential treatment option for patients with cancer-associated venous thromboembolism (VTE) [1–3]. Furthermore, a recent randomized clinical trial, the ONCO DVT study, revealed the potential benefit of extended anticoagulation therapy with edoxaban for patients with cancer-associated isolated distal deep vein thrombosis (DVT) in terms of thrombotic risks[4]. Whereas, there have been some concerns on an increased risk of bleeding with extended anticoagulation therapy with DOAC in patients with cancer-associated VTE.
